Quotient Clinical announced the completion of a major expansion of its pharmaceutical sciences facilities in March of 2011 in Nottingham. The GMP manufacturing suite has doubled in size and now incorporates six independent manufacturing rooms supporting oral, inhaled, and parenteral drug products. The formulation development and pharmaceutical analysis laboratory areas have also been significantly increased and now occupy an 11,000-sf purpose-built facility. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and are now fully operational.
The expansion is in response to the increasing demand for Quotient's RapidFACT (Rapid Formulation development And Clinical Testing) service. RapidFACT enables the efficient investigation and optimization of new drug product formulations in humans. Conventional development timelines are reduced by 50 to 60 percent and API consumption is reduced by up to 90 percent, delivering significant reductions in associated costs. RapidFACT is particularly effective in addressing the clinical problems associated with poorly soluble drugs or identifying optimal exposure profiles from modified release formulations. Quotient Clinical is a strategic business unit of drug development services provider Quotient Bioresearch.
